Adults with severe or moderately severe haemophilia B receiving etranacogene dezaparvovec in the HOPE-B phase 3 trial experience a stable increase in mean Factor IX activity levels and durable haemostatic protection after 24 months’ follow-up

GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark Pub Date : 2023-02-01 DOI:10.1055/s-0042-1760523

W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, M. Coppens, D. Cooper, R. Gut, S. Slawka, S. Verweij, R. Dolmetsch, Y. Li, P. Monahan, W. Miesbach

引用次数: 0

查看原文本刊更多论文

在HOPE-B iii期试验中，接受dezaparvovec的重度或中度血友病B成人患者在24个月的随访后，平均因子IX活性水平稳定增加，并具有持久的止血保护作用

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark

自引率

0.00%

发文量